Valuation OliX Pharmaceuticals, Inc

Stocks

End-of-day quote Korea S.E. 28/10/2026			5-day change	1st Jan Change
97,300.00 ^KRW	+7.40%		-0.31%	-30.70%

10-13	Roche Licenses Obesity Therapy From China's Rona in Up to $1.2 Billion Deal	DJ
08-14	OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027
Market Cap ¹	355,531	2,834,660	2,061,199	-
Change	-	697.3%	-27.29%	-
Enterprise Value (EV)	355,531	2,834,660	2,061,199	2,061,199
Change	-	697.3%	-27.29%	0%
P/E	-7.98x	-176x	-58.5x	-60.2x
PBR	-	-	30.2x	31.1x
PEG	-	2.6x	-0.6x	21.67x
Capitalization / Revenue	-	193x	258x	187x
EV / Revenue	-	0x	258x	187x
EV / EBITDA	-	-0x	-71.1x	-73.6x
EV / EBIT	-	-0x	-66.5x	-68.7x
EV / FCF	-	-	-60.6x	-62.5x
FCF Yield	-	-	-1.65%	-1.6%
Dividend per Share ²	-	-	-	-
Rate of return	-	-	-	-
EPS ²	-2,414	-800	-1,548	-1,505
Distribution rate	-	-	-	-
Net sales ¹	-	14.67	8	11
EBITDA ¹	-	-27.52	-29	-28
EBIT ¹	-	-30.46	-31	-30
Net income ¹	-19.1	-16.23	-31	-30
Net Debt	-	-	-	-
Reference price ²	19,260.00	140,400.00	90,600.00	90,600.00
Nbr of stocks (in thousands)	18,460	20,190	22,751	-
Announcement Date	3/21/25 A	2/12/26 A	-	-

¹KRW in Billions²KRW

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
OLIX PHARMACEUTICALS, INC	-58.53x	-	-	-	1.55B
WUXI APPTEC CO., LTD.	17.08x	6.33x	12.4x	1.75%	63.48B
ARGENX SE	30.03x	7.96x	26.08x	0.05%	54.55B
LONZA GROUP AG	37.03x	6.57x	19.63x	0.87%	53.59B
IQVIA HOLDINGS INC.	35.05x	3.37x	14.55x	-.--%	44.75B
BEONE MEDICINES AG	48.28x	5.55x	30.42x	-.--%	41.62B
REVOLUTION MEDICINES, INC.	-19.33x	186.93x	-20.57x	-.--%	39.91B
CELLTRION, INC.	30.28x	7.94x	20.6x	0.4%	32.47B
GENMAB A/S	36.51x	6.64x	22.27x	-.--%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	26.96x	5.67x	14.71x	-.--%	23.36B
Average	18.34x	26.33x	15.57x	0.34%	38.2B
Weighted average by Cap.	26.21x	25.23x	15.68x	0.46%